Silverarc Capital Management LLC Decreases Stock Position in ABIVAX Société Anonyme (NASDAQ:ABVX)

Silverarc Capital Management LLC trimmed its stake in shares of ABIVAX Société Anonyme (NASDAQ:ABVX - Free Report) by 38.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 285,120 shares of the company's stock after selling 176,540 shares during the quarter. Silverarc Capital Management LLC owned approximately 0.45% of ABIVAX Société Anonyme worth $2,087,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of ABVX. GAMMA Investing LLC purchased a new stake in ABIVAX Société Anonyme during the 4th quarter valued at $29,000. R Squared Ltd purchased a new position in ABIVAX Société Anonyme during the 4th quarter valued at about $36,000. Guggenheim Capital LLC bought a new position in ABIVAX Société Anonyme during the 4th quarter valued at approximately $92,000. Springhill Fund Asset Management HK Co Ltd bought a new stake in shares of ABIVAX Société Anonyme in the 4th quarter worth approximately $1,520,000. Finally, Kennedy Capital Management LLC raised its holdings in shares of ABIVAX Société Anonyme by 0.7% during the fourth quarter. Kennedy Capital Management LLC now owns 225,470 shares of the company's stock valued at $1,650,000 after acquiring an additional 1,656 shares in the last quarter. 47.91% of the stock is owned by hedge funds and other institutional investors.

ABIVAX Société Anonyme Price Performance

NASDAQ ABVX opened at $6.23 on Tuesday. ABIVAX Société Anonyme has a 12 month low of $4.77 and a 12 month high of $16.63. The stock's fifty day moving average price is $6.69 and its 200-day moving average price is $7.67.

Wall Street Analyst Weigh In

Several research analysts have commented on ABVX shares. JMP Securities restated a "market outperform" rating and issued a $33.00 price objective on shares of ABIVAX Société Anonyme in a report on Friday, January 10th. Morgan Stanley reaffirmed an "equal weight" rating and set a $12.00 price objective on shares of ABIVAX Société Anonyme in a research report on Thursday, March 20th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $38.00.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.